In October 2017, Incyte entered into a global collaboration and license agreement with us in which they obtained exclusive worldwide rights for the development and commercialization of MGA012, an anti-PD-1 antibody, in all indications. In addition to receiving an upfront payment, MacroGenics is eligible to receive milestones and royalties and retains the right to develop its pipeline assets in combination with MGA012. Learn more
Collaborations have been a critical part of MacroGenics’ growth strategy and will continue to be an emphasis for our future growth strategy. To date, the company has developed significant alliances with leading pharmaceutical and biotechnology companies that enable us to drive forward our proprietary programs, while retaining significant value in the downstream potential of our partnered programs.
The company is actively exploring alliances that complement our expertise in biologics product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms, product candidates and biologic product development capabilities.
MacroGenics’ Collaboration Partners
Incyte Corporation
Zai Lab Limited
In November 2018, we announced that Zai Lab had entered into an exclusive collaboration and license agreement with us for regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for margetuximab, MGD013 and an undisclosed multi-specific TRIDENT™ molecule in preclinical development. Learn more
I-Mab Biopharma
In July 2019, we announced that I-Mab Biopharma had entered into an exclusive collaboration and license agreement with us for regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for enoblituzumab. Learn more
Janssen
In December 2020, Janssen entered into a research collaboration and global license agreement with us to develop a preclinical bispecific molecule that incorporates MacroGenics’ proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.
Eversana
In November 2020, we announced that we had partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States. EVERSANA will utilize its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access-related services. EVERSANA and MacroGenics will equally share in funding EVERSANA’s commercialization expenses. EVERSANA will earn future revenue share payments which will be capped at 125% of their cumulative service fees.
Provention Bio
In 2018, we entered into multiple agreements with Provention Bio, Inc. pursuant to which we granted exclusive global rights for the purpose of developing and commercializing MGD010, a CD32B x CD79B DART molecule, for the treatment of autoimmune indications. In addition, Provention acquired our interest in teplizumab, a monoclonal antibody being developed for the treatment of type 1 diabetes. If Provention successfully develops, obtains regulatory approval for, and commercializes teplizumab, we will be eligible to receive up to $170 million in regulatory milestones, including $60 million upon BLA approval, and up to $225 million in commercial milestones
GC Pharma (Korea)
In July 2010, GC Pharma (formerly Green Cross) entered into a collaboration agreement with MacroGenics for the development and exclusive commercialization of margetuximab in South Korea.
NIAID/NIH
In September 2015, MacroGenics entered into a contract with the National Institute of Allergy and Infectious Diseases to perform product development and to advance DART product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with HIV infection (contract no. HHSN272201500032C). Learn more